Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

A new report shows while cancer death rates among Black people are declining, they remain higher than other racial and ethnic ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

Prostate cancer kills twice as many Black men as white men in the U.S. Beyoncé's father has signed onto a new $20 million ...

Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options live ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Anthos gained the rights from Novartis to develop abelacimab, a drug targeting stroke prevention and blood clots in those with atrial fibrillation, a heart rhythm disorder, and in cancer patients.